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Meningeal dissemination in primary CNS lymphoma:
prospective evaluation of 282 patients
Abstract
BACKGROUND: The impact of meningeal dissemination in primary CNS lymphoma (PCNSL) is
debated, and the reported frequency varies. We prospectively evaluated the diagnostic value of PCR in
comparison with CSF cytomorphology and MRI for diagnosing meningeal dissemination in PCNSL.
METHODS: We evaluated 282 patients from a multicenter therapy study for PCNSL for the presence of
meningeal dissemination: 205 with CSF cytomorphology, 171 with PCR of the rearranged
immunoglobulin heavy-chain genes in CSF, and 217 with cranial MRI. RESULTS: Meningeal
dissemination was found in 33 of 205 patients (16%) by cytomorphology, in 19 of 171 (11%) patients
evaluated by PCR, and in 8 of 217 patients (4%) by MRI. Considering either of these methods, the
relative frequency of meningeal dissemination was 17.4% (49 of 282 patients). PCR was monoclonal in
6 of 19 (32%) samples with positive cytomorphology, 1 of 13 samples (8%) with suspicious cytology,
and in 10 of 105 (10%) cytologically negative samples. In 11 samples with positive and 12 with
suspicious cytology, PCR showed only a polyclonal pattern. The probability of meningeal dissemination
detection was higher in cases with CSF pleocytosis (>5/microL) with an OR of 2.48 (95% CI 1.15-5.34,
p = 0.018). CSF protein had no predictive value for meningeal dissemination detection.
CONCLUSIONS: We found a low rate of meningeal dissemination in primary CNS lymphoma in this
large prospective study. The rate of discordant PCR and cytomorphologic results was high. Thus, the
methods should be regarded as complementary. CSF pleocytosis had predictive value for meningeal
dissemination detection.
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Abstract: 
Background: The impact of meningeal dissemination (MD) in primary CNS lymphoma 
(PCNSL) is still debated, and the reported frequency varies. We prospectively 
evaluated the diagnostic value of PCR in comparison with CSF cytomorphology and 
MRI for diagnosing MD in PCNSL.  
Methods: We evaluated 282 patients from a multicenter therapy study for PCNSL for 
the presence of MD: 205 with CSF cytomorphology, 171 with PCR of the rearranged 
immunoglobulin heavy-chain (IgH) genes in CSF and 217 with cranial MRI. 
Results: MD was found in 33 of 205 patients (16%) by cytomorphology, in 19 of 171 
(11%) patients evaluated by PCR and in 8 of 217 patients (4%) by MRI. Considering 
either of these methods, the relative frequency of MD was 17.4% (49 of 282 
patients). PCR was monoclonal in six of 19 (32%) samples with positive 
cytomorphology, one of 13 samples (8%) with suspicious cytology, and in ten of 105 
(10%) cytologically negative samples. In eleven samples with positive and twelve 
with suspicious cytology PCR showed only a polyclonal pattern. The probability of 
MD detection was higher in cases with CSF pleocytosis (>5/µl) with an odds ratio 
(OR) of 2.48 (95% CI 1.15-5.34, p=0.018). CSF protein had no predictive value for 
MD detection. 
Conclusions: We found a low rate of MD in PCNSL in this large prospective study. 
The rate of discordant PCR and cytomorphologic results was high. Thus, the 
methods should be regarded complementary. CSF pleocytosis had predictive value 
for MD detection. 
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Introduction: 
PCNSL is rare subtype of extranodal non-Hodgkin's lymphoma (NHL) confined to the 
CNS in the absence of systemic disease. Most cases are classified as diffuse large 
B-cell lymphoma 1. PCNSL is characterized by a poor prognosis as compared to 
systemic NHL with similar histology 2,3. Several clinical risk factors have been 
identified in PCNSL with performance status and age being the most powerful ones 
4,5. The prognostic impact of meningeal dissemination in PCNSL is unclear.  
The morphologic assessment of CSF is considered the gold standard in detecting 
MD in malignant disease 6, however, it fails to demonstrate malignant cells in up to 
41% of patients in whom leptomeningeal disease is thought to be present 7,8. The 
frequent false negative results are most often due to the paucity of tumor cells, which 
in part might be overcome by obtaining large CSF sample volumes and repeated 
sampling 6,9. On the other hand, in contrast to solid tumors, lymphoma cells may 
sometimes hardly be distinguished from reactive CSF lymphocytes, leading to false 
positive results. Furthermore, the frequent upfront use of corticosteroids in patients 
with symptomatic brain tumors represents another obstacle for the detection of 
lymphoma cells 10-12. CSF protein often is cited as adjuvant measurement, but its 
specificity for MD in PCNSL is low 13. The sensitivity of radiological detection of MD, 
ideally using MRI, is reported considerably lower in lymphoma as compared to solid 
tumors 14,15.  
It can be speculated that a more sensitive diagnostic method like PCR can enhance 
the diagnostic accuracy for detection of MD. Its value has not been systematically 
evaluated in a representative collective of PCNSL patients thus far.  
Here, we present the first prospective comparison of the diagnostic value of CSF 
cytomorphology, PCR of the rearranged IgH genes, and MRI in conjunction with cell 
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count and protein concentration for the detection of MD in PCNSL patients treated in 
a large multicenter study. 
 
Patients and treatment: 
Between 2001 and June 2007, immunocompetent patients with PCNSL enrolled into 
a German multicenter prospective randomized trial (G-PCNSL-SG1) were evaluated 
for the presence of MD by CSF examination (Fig. 1). For participating institutions, a 
neuro-oncologic experience was required 16. 
An approval for this study was obtained from the institutional ethics committee. 
Inclusion criteria were: immunocompetent patients with histologically or cytologically 
confirmed PCNSL, age 18 years or older, no previous therapy for PCNSL except 
corticosteroids, Karnofsky Performance Status (KPS) > 30% due to PCNSL or > 50% 
due to comorbidities, a creatinine clearance of at least 50ml/min, and written 
informed consent. All patients had cranial and, if clinically indicated additionally spinal 
gadolinium MRI prior to therapy; FLAIR MRI was not routinely performed. Systemic 
lymphoma manifestations were excluded by computed tomography (CT) of thorax 
and abdomen and a bone marrow biopsy. All patients were checked for intraocular 
spread by slit lamp examination.  
Primary therapy was not influenced by the diagnosis of MD, and consisted of six 
cycles HDMTX 4g/m2 intravenously over 4 hours every two weeks with a dose 
adjustment for creatinine clearance (CC) below 100ml/min (CC/100 * 4g/m2) prior to 
every course. Patients were randomized to receive immediate whole brain irradiation 
(WBI) with 45 Gy (1.5 Gy fractions) or WBI at relapse in case of complete remission 
(CR) after HDMTX, or to receive high-dose cytarabine 2 x 3g/m2/day intravenously 
over 2 days every 3 weeks up to 4 cycles or salvage WBI in case of no CR.  
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CSF analysis 
CSF was obtained by lumbar puncture before treatment and evaluated using 
standard methods for cell count, cytomorphology and protein immediately after 
sampling at the treating institution. Each case was interpreted by an experienced 
hematopathologist or neurologist. Normal values were defined as follows: CSF cells ≤ 
5/µl and CSF protein ≤ 45mg/dl. CSF cytology was termed positive for conclusive 
detection of lymphoma cells and suspicious when atypical lymphatic cells not clearly 
diagnostic of malignancy were detectable; the remaining cases were termed 
negative. 
A sample of 1.5 to 5ml (median 3.5ml) of native CSF was sent overnight at room 
temperature to our central molecular genetics laboratory for PCR examination. Here, 
DNA was extracted from cell pellets after centrifugation at the day of arrival using 
commercially available kits. DNA then was stored at -20°C until PCR analysis. All 
DNA extracts were controlled for their suitability as templates for IgH PCR by 
determination of the quantity (NanoDrop) and the quality (human growth hormone 
(HGH) PCR as control).  
Till March 2006, PCR of the rearranged IgH genes (Fig. 2) was performed as 
described recently 17,18. Briefly, a seminested PCR of the IgH chain CDR3 region was 
performed using the primers LJH in the first, VLJH in the second and FR3A in both 
PCR reactions 17. From April 2006 to June 2007, 18 samples were subjected to a 
PCR using three sets of family-specific IgH primers according to the BIOMED-2 
protocol, which was modified to apply 50 instead of 35 cycles for increased 
sensitivity. Three different framework region primer sets (FR1, FR2, and FR3) were 
applied separately to all samples in conjunction with a IgH joining segment (JH) 
consensus primer (JH22) 18,19.  
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In each PCR, positive (DNA from a B-cell line) and negative controls (sterile water) 
were included. All specimens were amplified at least twice in independent PCR runs 
to avoid false monoclonal interpretation of pseudoclonal rearrangement patterns 20. 
PCR products were subjected to an automated fluorescent fragment analysis. A 
monoclonal pattern was defined as the detection of a single or dominating amplicon 
of identical size in repetitive experiments. Multiple peaks characterized polyclonality. 
Patients with T-NHL were excluded from the PCR analysis. 
 
Neuroimaging: 
Brain MRIs were obtained before treatment and locally reviewed by an experienced 
neuroradiologist. A central neuroradiologic reference review was available. 
All examinations included T1- and T2-weighted sequences as well as contrast-
enhanced studies. Cerebral imaging was performed on various MR scanners with 
field strengths of 1.0 to 1.5 T. For the T1-weighted scans, all patients received 0.1 
mmol gadolinium-DTPA per kg body weight. MD on MRI was defined as contrast-
enhancement of the leptomeninges.  
 
Statistics: 
The software package SPSS for Windows release 14.0.1 was used for the statistical 
evaluation. A descriptive analysis of qualitiative and quantitative variables was 
performed and frequencies, median values and ranges given when applicable. The 
χ2 test was used to detect correlations between clinical and laboratory variables and 
the presence of MD and to inspect the missing patterns of the several diagnostic 
approaches. 
The diagnostic value of CSF pleocytosis and elevated protein was assessed using 
logistic regression, and the odds ratio (OR) for MD detection was calculated including 
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the two-sided 95% confidence interval (CI). Additionally, Kappa measures were 
calculated for each pair of MRI, PCR, and CSF. 
 
Results 
Patients and samples: 
A total of 282 patients were evaluated for the presence of MD: 205 with CSF 
cytomorphology, 171 with IgH PCR from CSF (Fig. 1), and 217 with MRI; in 102 
patients all three diagnostic methods were performed. The CSF samples were sent 
by 49 centers, including 20 university and 14 teaching hospitals accounting for 243 
(86%) of the samples.  
The median age of the patients was 62 (19 – 81) years, the median Karnofsky 
Performance Index 70 (30-100) %. There were 162 (57%) males and 120 females. 
The histologic diagnosis was diffuse large B cell lymphoma in 272 (97%) patients, 
small B cell lymphoma in nine (3%) and T-cell lymphoma in 1 (0.3%) patient. An 
ocular involvement was found in eight of 154 (5%) patients examined. Data on 
pretreatment with corticosteroids at the time of CSF sampling were available for 124 
patients (44%), of those only 14 (11.3%) patients were not on steroids.  
 
Detection of MD by CSF cytomorphology and PCR 
Lymphoma cells were detected in 33 of 205 (16.1%) patients tested. A suspicious 
CSF cytology was found in 20 patients (9.8%), a negative cytology in 152 (74%). A 
monoclonal PCR product was detected in 19 of 171 samples (11.1%), a polyclonal 
product in 113 (Fig. 3). In 39 (22.8%) samples, no IgH PCR product was detectable, 
in seven of those (4%) the HGH control PCR was also negative (termed as PCR 
failure in both cases). Fig. 1 shows the results of the molecular genetic analysis of 
171 patients with CSF cytomorphology as reference standard.  
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PCR was monoclonal in six of 19 samples (31.6%) with positive, one of 13 (7.7%) 
with suspicious and in ten of 105 (9.5%) with negative cytomorphology. In 11 of 19 
(57.9%) cytomorphologically positive samples and in 12 of 13 (92.3%) with 
suspicious cytomorphology, PCR showed only a polyclonal pattern. There were no 
significant differences concerning MD detection rate and PCR failure between both 
PCR protocols used. 
A positive cytomorphology was found in 15 of 94 (16%) patients on steroids versus 
two of 12 (17%) patients without steroids. PCR was monoclonal in 13 of 110 (12%) 
patients on steroids as compared to three of 14 (21%) patients without steroid 
pretreatment. The rate of PCR failure was 21% in patients with steroid treatment 
compared to 7% in those without. All these differences were not significant.  
 
Detection of MD by MRI 
Leptomeningeal enhancement was assessed by MRI in 217 patients, in eight (4%) 
MD was detected (Fig. 3B). Of those eight patients, CSF cytomorphology was 
positive in five of six tested patients and negative in one patient (no cytomorphologic 
examination in two patients). A monoclonal PCR product was found in two of four 
patients with MD on MRI (no PCR examination in four patients).  
 
Correlation of MD with laboratory and clinical findings  
There was a significant correlation of CSF cell count with MD defined as a positive 
result of any of the three methods (Table 1). Also, a significant correlation was found 
between CSF cell count and CSF cytomorphology with a cytological detection of 
lymphoma cells found in 17 of 74 (23%) patients with CSF pleocytosis as compared 
to 5 of 94 (5%) in patients normal CSF cell count (p=0.001). Abnormal CSF protein 
did not correlate with MD detection. The detection of lymphoma cells by PCR only did 
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not correlate with CSF pleocytosis, PCNSL localization or CSF protein. There was no 
correlation between detection of MD and age, gender, KPS, serum lactate 
dehydrogenase level and PCNSL localization (data not shown). 
 
Association of MRI, PCR and CSF 
We found no relationship between missing data from one of the three diagnostic 
procedures MRI, PCR, and CSF and the results of the other procedures. Thus we 
calculated pairwise Kappa measures for the MRI vs. PCR, MRI vs. CSF, and PCR 
vs. CSF for all cases in which data were available. These Kappa measures were 
rather small, 0.18 (PCR vs. CSF, p = 0.068), 0.19 (MRI vs. PCR, p = 0.013), and 0.27 
(MRI vs. CSF, p < 0.001). 
  
Discussion 
The relative frequency of MD in PCNSL reported thus far varies from 16% to 42% 
depending on the diagnostic procedures applied 9,13,21. The relatively low incidence of 
MD in our study is comparable to that found in more recent studies 3,21,22. The much 
higher frequency of 42% reported before resulted probably from the inclusion of 
patients with meningeal biopsy 9. Obtaining samples from the leptomeninges, 
however, is not included in clinical routine in PCNSL. When a positive CSF 
cytomorphology only was considered, a MD frequency of 26% was found in that 
study 9. A 60% rate of MD detected by PCR was reported in a retrospective study of 
15 PCNSL patients. However, multiple CSF samples from patients were evaluated 
over the course of their disease, including relapse 23.  
The introduction of putatively more sensitive methods such as flow cytometric 
immunophenotyping or PCR may enhance the diagnostic accuracy in detecting 
malignant cells in CSF. Only limited data is reported on both methods in lymphoma 
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patients 17,23-28, and there are no data on their systematic prospective evaluation in 
immunocompetent PCNSL patients. 
In this prospective multicenter study with 49 participating institutions, PCR analysis 
was only possible in a central laboratory, whereas a central cytomorphologic 
examination was not regarded practicable. This represents a limitation of our study.  
The use of steroids in the majority of patients but also the lack of data on steroid 
pretreatment in nearly half of the study population are further possible limitations. In 
PCNSL, diagnostic procedures are often reported to be hampered by corticosteroids 
due to their lymphocytotoxic effect. Pretreatment with corticosteroids in the majority 
of patients has also been a problem in all other diagnostic studies on PCNSL 9,17,23. 
We found no difference of MD frequency in patients with and without corticosteroids, 
however, the number of patients without corticosteroid pretreatment might have been 
too small to detect a significant difference.  
Radiological evaluation of the leptomeninges did not contribute considerably to the 
diagnostic process in our study, corresponding to findings made by others 14.  
We could confirm the predictive value of CSF pleocytosis for MD 13 (both detected by 
cytomorphology and defined as a positive result of any of the methods used). 
However, the presence of pleocytosis might have biased the decision to diagnose 
malignant cells. Interestingly, we did not see a correlation of CSF pleocytosis with a 
positive PCR result. Elevated CSF protein was not associated with MD in this study. 
Since it has been reported to have prognostic value in PCNSL29, it may rather reflect 
tumor burden or location without being associated with MD. 
The high rate of discordant results of cytomorphology and PCR is the most striking 
finding of this study. Lymphoma cells were confirmed by PCR in only 32% of 
cytomorphologically positive samples, whereas polyclonal B cells were detected in 
58%.  
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This might be due to a considerable rate of PCR false negatives. In one study, PCR 
failed to demonstrate clonality in 23% of biopsy samples of immunohistologically 
proven PCNSL 30. As compared to nodal diffuse large B-cell lymphomas, PCNSL 
have an especially high mutational frequency due to the introduction of further point 
mutations after Ig gene rearrangement, which can prevent annealing of PCR primers 
31,32. Corticosteroid pretreatment might have also increased the rate of PCR 
negatives, since PCR failure was more frequent in patients with corticosteroid 
pretreatment. However, the presence of false positive cytology results cannot be 
finnaly ruled out.  Conversely, only 35% of samples with a monoclonal PCR result 
were recognized cytomorphologically, whereas 59% were not. False positive PCR 
results due to contamination or misinterpretation of a band from a single B cell as 
monoclonal (“pseudomonoclonality”) cannot be ruled out. The latter problem occurs 
frequently when assessing paucicellular specimens with PCR 33,34. We tried to 
minimize this problem by repeated assessment in independent PCR runs as it has 
been reported for gastric lymphoma 35. In the only larger comparable study, which 
used IgH PCR for MD detection in 68 PCNSL patients retrospectively, discordant 
PCR and cytology results were also frequent 17 
Given the limitations inherent in the diagnostic methods used, our results indicate 
that CSF cytomorpholgy and IgH PCR should be considered complementary 
methods for MD detection in PCNSL. The possible impact of MD detection by PCR 
and cytology on clinical outcome in our study remains to be evaluated. 
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Table 1: Probability of MD* in patients with CSF pleocytosis or elevated CSF protein  
 No. of 
pts. 
No. of pts. 
with MD* 
OR (95% CI) 
 
p 
CSF pleocytosis:     
no 102 13 (12.7%)
yes 79 21 (26.6%)
2.48 
(1.15 - 5.34) 
0.018 
missing 101 15 (14.9%)   
CSF protein:     
normal 54 9 (16.7%) 
elevated 129 25 (19.4%)
1.20 
(0.52 - 2.78) 
0.67 
missing 99 15 (15.2%)   
 
*defined as a positive result of any of the three methods used (cytomorphology, PCR 
or MRI) 
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Figure legends: 
 
Fig. 1: Flow diagram of eligible patients 
 
Fig. 2: Principle of IgH rearrangement and its detection by PCR 
During B cell development the IgH gene undergoes a complex rearrangement among 
their variable (V), diversity (D) and joining (J) germline gene segments (C – constant 
segment). This includes random insertion of nucleotides (N) at the V–D and D–J 
junctions resulting in a short hypervariable gene sequence; the third Complementary 
Determining Region (CDR3) which is unique for each B-lymphocyte 36. 
A PCR using primers (→) which encompass the CDR3 region by annealing in the 
relatively conserved framework (FR1-3) and joining regions can detect clonal B cells. 
 
Fig. 3: Representative images of MD detection 
CSF cytyomorphology (A) showing atypical lymphoma cells next to small reactive 
lymphocytes, PCR fragment analysis (B) demonstrating a pseudomonoclonal 
(lanes 1, 2), monoclonal (lanes 3, 4), and polyclonal (lanes 5, 6) pattern, and Gadolinium 
enhanced MRI (C) with cerebellar meningeal enhancement (white arrow). 
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